Literature DB >> 1555991

Relationships among tumor temperature, treatment time, and histopathological outcome using preoperative hyperthermia with radiation in soft tissue sarcomas.

K A Leopold1, M Dewhirst, T Samulski, J Harrelson, J A Tucker, S L George, R K Dodge, W Grant, S Clegg, L R Prosnitz.   

Abstract

The lack of an unambiguous thermal dosimetry continues to impede progress in clinical hyperthermia. In an attempt to define better this dosimetry, a model based on the cumulative minutes during which arbitrary percentages of measured tumor temperature points exceeded an index temperature was tested in patients with soft tissue sarcomas treated with preoperative hyperthermia and conventional radiation therapy. Patients received 5000-5040 cGy at 180-200 cGy per fraction. Hyperthermia was delivered 30-60 minutes after radiation therapy and given for 60 minutes. Patients were randomized between one and two hyperthermia treatments per week for a total of five or 10 treatments, respectively. Lesions were excised 4-6 weeks after completion of hyperthermia/radiation therapy. Successful treatment outcome was considered to be the finding of greater than 80% necrosis of the sarcoma upon histopathologic examination of the resected specimen. Forty-five patients were eligible with thermometry data available in 44 patients. An average of 19 interstitial sites were monitored each treatment per tumor. Sixty percent of tumors had a successful histopathologic outcome. Univariate analysis demonstrated that several descriptors of the temperature distribution were strongly related to treatment outcome; more strongly than nonthermometric factors, such as the number of treatments per week, tumor volume and patient age and more strongly than the commonly used temperature descriptors Tmin and Tmax. Descriptors that incorporated both temperature and time were also superior to the more commonly used descriptors Tmin and Tmax. Multivariate stepwise logistic regression analysis revealed that a descriptor of both the hyperthermia treatment time and the frequency distribution of intratumoral temperatures was the strongest predictor of histopathologic outcome and that the best predictive model combined this time/temperature descriptor and one versus two treatment per week grouping. The more conventional temperature descriptor, minimum measured tumor temperature, did not significantly enhance the predictive power of treatment group. Based on these results, we recommend that descriptors based on both the frequency distribution of intratumoral temperatures and hyperthermia treatment time be tested for relationships with treatment outcome in other clinical data bases. Furthermore, we recommend that temperature descriptors that are less sensitive to catheter placement and tumor boundary identification than Tmin and Tmax (such as T90, T50, and T10) be tested prospectively along with other important thermal variables in Phase II trials in further efforts to define a thermal dosimetry for spatially nonuniform temperature distributions.

Entities:  

Mesh:

Year:  1992        PMID: 1555991     DOI: 10.1016/0360-3016(92)90798-m

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  13 in total

1.  Nanoscale Drug Delivery and Hyperthermia: The Materials Design and Preclinical and Clinical Testing of Low Temperature-Sensitive Liposomes Used in Combination with Mild Hyperthermia in the Treatment of Local Cancer.

Authors:  Chelsea D Landon; Ji-Young Park; David Needham; Mark W Dewhirst
Journal:  Open Nanomed J       Date:  2011-01-01

Review 2.  Palliative cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion: current clinical practice or misnomer?

Authors:  Laura A Lambert; Ariana Harris
Journal:  J Gastrointest Oncol       Date:  2016-02

3.  Radiofrequency capacitive hyperthermia for unresectable hepatic cancers.

Authors:  K Yamamoto; Y Tanaka
Journal:  J Gastroenterol       Date:  1997-06       Impact factor: 7.527

Review 4.  Hyperthermia in soft tissue sarcoma.

Authors:  Lars H Lindner; Rolf D Issels
Journal:  Curr Treat Options Oncol       Date:  2011-03

Review 5.  Present and future technology for simultaneous superficial thermoradiotherapy of breast cancer.

Authors:  Eduardo G Moros; Jose Peñagaricano; Petr Novàk; William L Straube; Robert J Myerson
Journal:  Int J Hyperthermia       Date:  2010       Impact factor: 3.914

6.  Thermal dose is related to duration of local control in canine sarcomas treated with thermoradiotherapy.

Authors:  Donald E Thrall; Susan M LaRue; Daohai Yu; Thaddeus Samulski; Linda Sanders; Beth Case; Gary Rosner; Chieko Azuma; Jeannie Poulson; Amy F Pruitt; Wilma Stanley; Marlene L Hauck; Laurel Williams; Paul Hess; Mark W Dewhirst
Journal:  Clin Cancer Res       Date:  2005-07-15       Impact factor: 12.531

7.  Biological cell survival mapping for radiofrequency intracavitary hyperthermia combined with simultaneous high dose-rate intracavitary irradiation.

Authors:  H Kurosaki; H Sakurai; N Mitsuhashi; Y Tamaki; T Akimoto; T Takahashi; M Furuta; J I Saitoh; K Hayakawa; H Niibe
Journal:  Jpn J Cancer Res       Date:  2001-01

8.  Design, Implementation, Evaluation and Application of a 32-Channel Radio Frequency Signal Generator for Thermal Magnetic Resonance Based Anti-Cancer Treatment.

Authors:  Haopeng Han; Thomas Wilhelm Eigentler; Shuailin Wang; Egor Kretov; Lukas Winter; Werner Hoffmann; Eckhard Grass; Thoralf Niendorf
Journal:  Cancers (Basel)       Date:  2020-06-28       Impact factor: 6.639

9.  Combined effects of an angiogenesis inhibitor (TNP-470) and hyperthermia.

Authors:  Y Nishimura; R Murata; M Hiraoka
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

10.  Modelling mass and heat transfer in nano-based cancer hyperthermia.

Authors:  M Nabil; P Decuzzi; P Zunino
Journal:  R Soc Open Sci       Date:  2015-10-21       Impact factor: 2.963

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.